Health Care Health Care   The Big Story MAHA leaders heading for clash over GLP-1 drugs Two of President-elect Trump’s top health nominees are on a collision course as the

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial decision on coverage for groundbreaking anti-obesity drugs. Mehmet Oz, Trump’s pick to run the Centers for Medicare and Medicaid Services,

“While no drug is without side effects, health problems associated with obesity almost certainly exceed the risks of GLP-1 agonists,” Musk said as early as Oct. 2023. GLP-1 agonists are a class of medications that can help manage Type 2 diabetes and obesity.

The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr. may not be such a fan.

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear whether Trump's administration will see it through.

This comes as Robert F. Kennedy JR. (RFK), who president-elect Donald Trump tapped to lead the Department of Health and Human Services, has shared his disapproval of the drugs’ popularity.

Elon Musk turned heads with a decadent his tree. Dressed head-to-toe in a Santa costume, he captioned his photo "Ozempic Santa," flaunting a slimmer figure. The Tesla CEO was picked by president-elect Donald Trump to co-lead the inaugural Department of Government Efficiency shortly after the election.

Elon Musk recently shared a post on X, revealing he uses the weight loss drug Mounjaro. Musk posed in a Santa Claus outfit by a holiday tree and captioned the post, "Ozempic Santa," later clarifying he uses Mounjaro.

Elon Musk has revealed he has switched to a more powerful weight-loss drug, sharing the news alongside a photo of himself dressed as Father Christmas. The SpaceX billionaire, 53, posted a picture of himself slimmed down in a red-and-white fur-lined suit with the caption: "Ozempic Santa".